Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis

Diana Pang, Masha Kocherginsky, Thomas Krausz, So Young Kim, Suzanne D. Conzen

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Glucocorticoid receptor (GR) activation has recently been implicated in the initiation of anti-apoptotic signaling pathways in epithelial cell lines grown in culture. However, the evidence that GR-mediated inhibition of tumor cell apoptosis is the mechanism that diminishes chemotherapy effectiveness in vivo is limited. We therefore initiated a breast cancer xenograft study to examine whether or not pretreatment with glucocorticoids (GCs) decreases tumor response to chemotherapy by inhibiting tumor cell apoptosis. Here we report a significant decrease in paclitaxel-induced apoptosis in xenografts from mice pretreated with dexamethasone (Dex). A significant difference in apoptosis in xenografts from Dex/paclitaxel versus paclitaxel treated animals was seen eight days following initiation of chemotherapy. Nine days later, mice treated with Dex/paclitaxel had significantly larger tumors compared with those that received paclitaxel alone (p = 0.032). Dex pretreatment did not significantly affect tumor cell proliferation rates. Taken together, these results demonstrate that systemic Dex administration results in significantly reduced breast cancer xenograft apoptosis in the context of chemotherapy treatment. We also found that systemic Dex treatment results in upregulation of the anti-apoptotic gene MKP-1 and downregulation of pro-apoptotic Bid and TRAIL genes in tumor cells six hours following Dex treatment. These in vivo gene expression changes correlated with significant inhibition of chemotherapy-induced apoptosis. Interestingly, the decreased chemotherapeutic response of Dex-pretreated tumors persisted for several weeks following treatment. These data suggest that GR-mediated transcriptional regulation of pro- and anti-apoptotic genes contributes to the mechanism through which GCs decrease paclitaxel-induced apoptosis.

Original languageEnglish (US)
Pages (from-to)933-940
Number of pages8
JournalCancer Biology and Therapy
Volume5
Issue number8
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Paclitaxel
Heterografts
Dexamethasone
Apoptosis
Neoplasms
Glucocorticoid Receptors
Drug Therapy
Glucocorticoids
Breast Neoplasms
Genes
Therapeutics
Up-Regulation
Down-Regulation
Epithelial Cells
Cell Proliferation
Gene Expression
Cell Line

Keywords

  • Apoptosis
  • Breast cancer
  • Dexamethasone
  • Glucocorticoids
  • Paclitaxel
  • Q-RT-PCR
  • Xenograft

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis. / Pang, Diana; Kocherginsky, Masha; Krausz, Thomas; Kim, So Young; Conzen, Suzanne D.

In: Cancer Biology and Therapy, Vol. 5, No. 8, 08.2006, p. 933-940.

Research output: Contribution to journalArticle

Pang, Diana ; Kocherginsky, Masha ; Krausz, Thomas ; Kim, So Young ; Conzen, Suzanne D. / Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis. In: Cancer Biology and Therapy. 2006 ; Vol. 5, No. 8. pp. 933-940.
@article{237ecc7452f6483f8360f17310e39335,
title = "Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis",
abstract = "Glucocorticoid receptor (GR) activation has recently been implicated in the initiation of anti-apoptotic signaling pathways in epithelial cell lines grown in culture. However, the evidence that GR-mediated inhibition of tumor cell apoptosis is the mechanism that diminishes chemotherapy effectiveness in vivo is limited. We therefore initiated a breast cancer xenograft study to examine whether or not pretreatment with glucocorticoids (GCs) decreases tumor response to chemotherapy by inhibiting tumor cell apoptosis. Here we report a significant decrease in paclitaxel-induced apoptosis in xenografts from mice pretreated with dexamethasone (Dex). A significant difference in apoptosis in xenografts from Dex/paclitaxel versus paclitaxel treated animals was seen eight days following initiation of chemotherapy. Nine days later, mice treated with Dex/paclitaxel had significantly larger tumors compared with those that received paclitaxel alone (p = 0.032). Dex pretreatment did not significantly affect tumor cell proliferation rates. Taken together, these results demonstrate that systemic Dex administration results in significantly reduced breast cancer xenograft apoptosis in the context of chemotherapy treatment. We also found that systemic Dex treatment results in upregulation of the anti-apoptotic gene MKP-1 and downregulation of pro-apoptotic Bid and TRAIL genes in tumor cells six hours following Dex treatment. These in vivo gene expression changes correlated with significant inhibition of chemotherapy-induced apoptosis. Interestingly, the decreased chemotherapeutic response of Dex-pretreated tumors persisted for several weeks following treatment. These data suggest that GR-mediated transcriptional regulation of pro- and anti-apoptotic genes contributes to the mechanism through which GCs decrease paclitaxel-induced apoptosis.",
keywords = "Apoptosis, Breast cancer, Dexamethasone, Glucocorticoids, Paclitaxel, Q-RT-PCR, Xenograft",
author = "Diana Pang and Masha Kocherginsky and Thomas Krausz and Kim, {So Young} and Conzen, {Suzanne D.}",
year = "2006",
month = "8",
doi = "10.4161/cbt.5.8.2875",
language = "English (US)",
volume = "5",
pages = "933--940",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis

AU - Pang, Diana

AU - Kocherginsky, Masha

AU - Krausz, Thomas

AU - Kim, So Young

AU - Conzen, Suzanne D.

PY - 2006/8

Y1 - 2006/8

N2 - Glucocorticoid receptor (GR) activation has recently been implicated in the initiation of anti-apoptotic signaling pathways in epithelial cell lines grown in culture. However, the evidence that GR-mediated inhibition of tumor cell apoptosis is the mechanism that diminishes chemotherapy effectiveness in vivo is limited. We therefore initiated a breast cancer xenograft study to examine whether or not pretreatment with glucocorticoids (GCs) decreases tumor response to chemotherapy by inhibiting tumor cell apoptosis. Here we report a significant decrease in paclitaxel-induced apoptosis in xenografts from mice pretreated with dexamethasone (Dex). A significant difference in apoptosis in xenografts from Dex/paclitaxel versus paclitaxel treated animals was seen eight days following initiation of chemotherapy. Nine days later, mice treated with Dex/paclitaxel had significantly larger tumors compared with those that received paclitaxel alone (p = 0.032). Dex pretreatment did not significantly affect tumor cell proliferation rates. Taken together, these results demonstrate that systemic Dex administration results in significantly reduced breast cancer xenograft apoptosis in the context of chemotherapy treatment. We also found that systemic Dex treatment results in upregulation of the anti-apoptotic gene MKP-1 and downregulation of pro-apoptotic Bid and TRAIL genes in tumor cells six hours following Dex treatment. These in vivo gene expression changes correlated with significant inhibition of chemotherapy-induced apoptosis. Interestingly, the decreased chemotherapeutic response of Dex-pretreated tumors persisted for several weeks following treatment. These data suggest that GR-mediated transcriptional regulation of pro- and anti-apoptotic genes contributes to the mechanism through which GCs decrease paclitaxel-induced apoptosis.

AB - Glucocorticoid receptor (GR) activation has recently been implicated in the initiation of anti-apoptotic signaling pathways in epithelial cell lines grown in culture. However, the evidence that GR-mediated inhibition of tumor cell apoptosis is the mechanism that diminishes chemotherapy effectiveness in vivo is limited. We therefore initiated a breast cancer xenograft study to examine whether or not pretreatment with glucocorticoids (GCs) decreases tumor response to chemotherapy by inhibiting tumor cell apoptosis. Here we report a significant decrease in paclitaxel-induced apoptosis in xenografts from mice pretreated with dexamethasone (Dex). A significant difference in apoptosis in xenografts from Dex/paclitaxel versus paclitaxel treated animals was seen eight days following initiation of chemotherapy. Nine days later, mice treated with Dex/paclitaxel had significantly larger tumors compared with those that received paclitaxel alone (p = 0.032). Dex pretreatment did not significantly affect tumor cell proliferation rates. Taken together, these results demonstrate that systemic Dex administration results in significantly reduced breast cancer xenograft apoptosis in the context of chemotherapy treatment. We also found that systemic Dex treatment results in upregulation of the anti-apoptotic gene MKP-1 and downregulation of pro-apoptotic Bid and TRAIL genes in tumor cells six hours following Dex treatment. These in vivo gene expression changes correlated with significant inhibition of chemotherapy-induced apoptosis. Interestingly, the decreased chemotherapeutic response of Dex-pretreated tumors persisted for several weeks following treatment. These data suggest that GR-mediated transcriptional regulation of pro- and anti-apoptotic genes contributes to the mechanism through which GCs decrease paclitaxel-induced apoptosis.

KW - Apoptosis

KW - Breast cancer

KW - Dexamethasone

KW - Glucocorticoids

KW - Paclitaxel

KW - Q-RT-PCR

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=33751167213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751167213&partnerID=8YFLogxK

U2 - 10.4161/cbt.5.8.2875

DO - 10.4161/cbt.5.8.2875

M3 - Article

C2 - 16775428

AN - SCOPUS:33751167213

VL - 5

SP - 933

EP - 940

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 8

ER -